B-intervention	0	12	Preoperative
I-intervention	13	26	dexamethasone
O	27	34	reduces
B-condition	35	48	postoperative
I-condition	49	53	pain
I-condition	53	54	,
I-condition	55	61	nausea
I-condition	62	65	and
I-condition	66	74	vomiting
O	75	84	following
O	85	95	mastectomy
O	96	99	for
O	100	106	breast
O	107	113	cancer
O	113	114	.

O	115	128	Dexamethasone
O	129	132	has
O	133	137	been
O	138	146	reported
O	147	149	to
O	150	156	reduce
O	157	170	postoperative
O	171	179	symptoms
O	180	185	after
O	186	195	different
O	196	204	surgical
O	205	215	procedures
O	215	216	.

O	217	219	We
O	220	229	evaluated
O	230	233	the
O	234	242	efficacy
O	243	245	of
O	246	258	preoperative
O	259	272	dexamethasone
O	273	275	in
O	276	288	ameliorating
O	289	302	postoperative
O	303	309	nausea
O	310	313	and
O	314	322	vomiting
O	323	324	(
O	324	328	PONV
O	328	329	)
O	329	330	,
O	331	334	and
O	335	339	pain
O	340	345	after
O	346	356	mastectomy
O	356	357	.

O	358	360	In
O	361	365	this
O	366	377	prospective
O	377	378	,
O	379	385	double
O	385	386	-
O	386	391	blind
O	391	392	,
O	393	400	placebo
O	400	401	-
O	401	411	controlled
O	412	417	study
O	417	418	,
B-total-participants	419	421	70
B-eligibility	422	430	patients
I-eligibility	431	440	scheduled
I-eligibility	441	444	for
I-eligibility	445	455	mastectomy
I-eligibility	456	460	with
I-eligibility	461	469	axillary
I-eligibility	470	475	lymph
I-eligibility	476	480	node
I-eligibility	481	491	dissection
O	492	496	were
O	497	505	analyzed
O	506	511	after
O	512	525	randomization
O	526	528	to
O	529	538	treatment
O	539	543	with
O	544	545	8
O	546	548	mg
O	549	560	intravenous
O	561	574	dexamethasone
O	575	576	(
O	576	577	n
O	578	579	=
B-intervention-participants	580	582	35
O	582	583	)
O	584	586	or
B-control	587	594	placebo
O	595	596	(
O	596	597	n
O	598	599	=
B-intervention-participants	600	602	35
O	602	603	)
O	603	604	.

O	605	608	All
O	609	617	patients
O	618	627	underwent
O	628	640	standardized
O	641	651	procedures
O	652	655	for
O	656	663	general
O	664	674	anesthesia
O	675	678	and
O	679	686	surgery
O	686	687	.

O	688	696	Episodes
O	697	699	of
O	700	704	PONV
O	705	708	and
O	709	713	pain
O	714	719	score
O	720	724	were
O	725	733	recorded
O	734	736	on
O	737	738	a
O	739	745	visual
O	746	754	analogue
O	755	760	scale
O	760	761	.

O	762	771	Analgesic
O	772	775	and
O	776	786	antiemetic
O	787	799	requirements
O	800	804	were
O	805	809	also
O	810	818	recorded
O	818	819	.

O	820	831	Demographic
O	832	835	and
O	836	843	medical
O	844	853	variables
O	854	858	were
O	859	866	similar
O	867	874	between
O	875	881	groups
O	881	882	.

O	883	886	The
B-outcome	887	896	incidence
I-outcome	897	899	of
I-outcome	900	904	PONV
O	905	908	was
O	909	914	lower
O	915	917	in
O	918	921	the
O	922	935	dexamethasone
O	936	941	group
B-outcome	942	944	at
I-outcome	945	948	the
I-outcome	949	954	early
I-outcome	955	968	postoperative
I-outcome	969	979	evaluation
O	980	981	(
B-iv-bin-percent	981	983	28
I-iv-bin-percent	983	984	.
I-iv-bin-percent	984	985	6
I-iv-bin-percent	985	986	%
O	987	989	vs
O	989	990	.
B-cv-bin-percent	991	993	60
I-cv-bin-percent	993	994	%
O	994	995	;
O	996	997	p
O	998	999	=
O	1000	1001	0
O	1001	1002	.
O	1002	1004	02
O	1004	1005	)
O	1006	1009	and
B-outcome	1010	1012	at
I-outcome	1013	1014	6
I-outcome	1015	1016	h
O	1017	1018	(
B-iv-bin-percent	1018	1020	17
I-iv-bin-percent	1020	1021	.
I-iv-bin-percent	1021	1022	2
I-iv-bin-percent	1022	1023	%
O	1024	1026	vs
O	1026	1027	.
B-cv-bin-percent	1028	1030	45
I-cv-bin-percent	1030	1031	.
I-cv-bin-percent	1031	1032	8
I-cv-bin-percent	1032	1033	%
O	1033	1034	;
O	1035	1036	p
O	1037	1038	=
O	1039	1040	0
O	1040	1041	.
O	1041	1043	03
O	1043	1044	)
O	1044	1045	.

O	1046	1050	More
O	1051	1059	patients
O	1060	1062	in
O	1063	1066	the
O	1067	1074	placebo
O	1075	1080	group
B-outcome	1081	1089	required
I-outcome	1090	1100	additional
I-outcome	1101	1111	antiemetic
I-outcome	1112	1122	medication
O	1123	1124	(
B-cv-bin-abs	1124	1126	21
O	1127	1129	vs
O	1129	1130	.
B-iv-bin-abs	1131	1132	8
O	1132	1133	;
O	1134	1135	p
O	1136	1137	=
O	1138	1139	0
O	1139	1140	.
O	1140	1142	01
O	1142	1143	)
O	1143	1144	.

O	1145	1158	Dexamethasone
O	1159	1168	treatment
O	1169	1182	significantly
O	1183	1190	reduced
B-outcome	1191	1204	postoperative
I-outcome	1205	1209	pain
I-outcome	1210	1214	just
I-outcome	1215	1220	after
I-outcome	1221	1228	surgery
O	1229	1230	(
O	1230	1233	VAS
O	1234	1239	score
O	1239	1240	,
B-iv-cont-mean	1241	1242	4
I-iv-cont-mean	1242	1243	.
I-iv-cont-mean	1243	1245	54
O	1246	1247	±
B-iv-cont-sd	1248	1249	1
I-iv-cont-sd	1249	1250	.
I-iv-cont-sd	1250	1252	55
O	1253	1255	vs
O	1255	1256	.
B-cv-cont-mean	1257	1258	5
I-cv-cont-mean	1258	1259	.
I-cv-cont-mean	1259	1261	83
O	1262	1263	±
B-cv-cont-sd	1264	1265	2
I-cv-cont-sd	1265	1266	.
I-cv-cont-sd	1266	1268	00
O	1268	1269	;
O	1270	1271	p
O	1272	1273	=
O	1274	1275	0
O	1275	1276	.
O	1276	1279	004
O	1279	1280	)
O	1280	1281	,
B-outcome	1282	1284	at
I-outcome	1285	1286	6
I-outcome	1287	1288	h
O	1289	1290	(
B-iv-cont-mean	1290	1291	3
I-iv-cont-mean	1291	1292	.
I-iv-cont-mean	1292	1294	03
O	1295	1296	±
B-iv-cont-sd	1297	1298	1
I-iv-cont-sd	1298	1299	.
I-iv-cont-sd	1299	1301	20
O	1302	1304	vs
O	1304	1305	.
B-cv-cont-mean	1306	1307	4
I-cv-cont-mean	1307	1308	.
I-cv-cont-mean	1308	1310	17
O	1311	1312	±
B-cv-cont-sd	1313	1314	1
I-cv-cont-sd	1314	1315	.
I-cv-cont-sd	1315	1317	24
O	1317	1318	;
O	1319	1320	p
O	1321	1322	<
O	1323	1324	0
O	1324	1325	.
O	1325	1329	0005
O	1329	1330	)
O	1331	1334	and
B-outcome	1335	1337	at
I-outcome	1338	1340	12
I-outcome	1341	1342	h
O	1343	1344	(
B-iv-cont-mean	1344	1345	2
I-iv-cont-mean	1345	1346	.
I-iv-cont-mean	1346	1348	09
O	1349	1350	±
B-iv-cont-sd	1351	1352	0
I-iv-cont-sd	1352	1353	.
I-iv-cont-sd	1353	1355	85
O	1356	1358	vs
O	1358	1359	.
B-cv-cont-mean	1360	1361	2
I-cv-cont-mean	1361	1362	.
I-cv-cont-mean	1362	1364	54
O	1365	1366	±
B-cv-cont-sd	1367	1368	0
I-cv-cont-sd	1368	1369	.
I-cv-cont-sd	1369	1371	98
O	1371	1372	;
O	1373	1374	p
O	1375	1376	=
O	1377	1378	0
O	1378	1379	.
O	1379	1381	04
O	1381	1382	)
O	1382	1383	.

B-outcome	1384	1394	Analgesics
O	1395	1399	were
O	1400	1408	required
O	1409	1411	in
O	1412	1416	more
O	1417	1425	patients
O	1426	1428	of
O	1429	1432	the
O	1433	1440	control
O	1441	1446	group
O	1447	1448	(
B-cv-bin-abs	1448	1450	21
O	1451	1453	vs
O	1453	1454	.
B-iv-bin-abs	1455	1457	10
O	1457	1458	;
O	1459	1460	p
O	1461	1462	=
O	1463	1464	0
O	1464	1465	.
O	1465	1468	008
O	1468	1469	)
O	1469	1470	.

O	1471	1476	There
O	1477	1481	were
O	1482	1484	no
B-outcome	1485	1492	adverse
I-outcome	1493	1499	events
I-outcome	1499	1500	,
I-outcome	1501	1510	morbidity
I-outcome	1511	1513	or
I-outcome	1514	1523	mortality
O	1523	1524	.

O	1525	1537	Preoperative
O	1538	1549	intravenous
O	1550	1563	dexamethasone
O	1564	1565	(
O	1565	1566	8
O	1567	1569	mg
O	1569	1570	)
O	1571	1574	can
O	1575	1588	significantly
O	1589	1595	reduce
O	1596	1599	the
O	1600	1609	incidence
O	1610	1612	of
O	1613	1617	PONV
O	1618	1621	and
O	1622	1626	pain
O	1627	1629	in
O	1630	1638	patients
O	1639	1649	undergoing
O	1650	1660	mastectomy
O	1661	1665	with
O	1666	1674	axillary
O	1675	1685	dissection
O	1686	1689	for
O	1690	1696	breast
O	1697	1703	cancer
O	1703	1704	.

O	1705	1716	NCT01116713
O	1716	1717	.
